Physician profile
Daniel O Thompson
NPI 1831186717
$4,022.45
in general payments reported to CMS, 2019-2025
37 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $441 · 2021: $700 · 2022: $667 · 2023: $629 · 2024: $696 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $936.13 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $438.11 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $384.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $193.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $188.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $177.67 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $137.49 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.34 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $127.48 | 2019-2023 | |
| Boston Scientific Corporation | $118.35 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Medical Device Business Services, INC. | $103.62 | 2024 | Velys |
| Amarin Pharma, INC. | $94.96 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.36 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $81.86 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Amgen INC. | $81.17 | 2019-2025 | Otezla, Repatha, Krystexxa |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.